Navigation Links
ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
Date:10/23/2007

- Interim data shows promise as a potential treatment for kidney cancer -

SEATTLE, Oct. 23 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (Nasdaq: ZGEN) today presented positive Phase 1 interim data from a Phase 1/2 trial of Interleukin 21 (IL-21) in combination with Nexavar(R) (sorafenib) in patients with renal cell cancer. Preliminary data from the Phase 1 trial suggests that the combination of IL-21 and sorafenib is well tolerated, with a toxicity profile similar to known toxicities of each agent alone. This combination therapy has also shown promising anti-tumor activity.

"IL-21's unique mechanism of action makes it an ideal potential candidate for combination with approved targeted agents in renal cell cancer," said Nicole Onetto, M.D., Senior Vice President and Chief Medical Officer of ZymoGenetics. "We were very pleased to see that the combination of IL-21 and Nexavar can be safely administered for repeated courses, and that the majority of patients treated to date experience tumor shrinkage. The Phase 2 part of this trial should allow us to confirm these promising results."

Results were presented at the AACR-NCI-EORTC International Conference on "Molecular Targets and Cancer Therapeutics" held in San Francisco. ZymoGenetics is in the process of finishing the Phase 1 part of the study evaluating the combination therapy in patients with clear cell histology, which accounts for 85% of all renal cell tumors. The Phase 2 portion of the study is expected to begin before year end and will examine a larger patient group treated with the maximum tolerated dose of IL-21.

To date, a total of 13 evaluable patients have been enrolled in the Phase 1 portion of the study and treated at one of three dose levels (10, 30 and 50 mcg/kg of IL-21). Treatment consists of IL-21 administered IV on days 1-5 and 15-19 of a 6 week treatment course in combination with sorafenib administered at the recommended dose of 400 mg twice a day. Patients with Stable D
'/>"/>

SOURCE ZymoGenetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Medina ... as CEO and member of the Board of Directors ... of medical device development and commercialization experience, including over ... Mr. Engelson previously served as a Partner of the ... President and CEO of two Foundry start-ups. Mr. Engelson ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... , August 29, 2014 ... Seed Oil Market by Extraction type (SFE, Cold ... & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) ... by MarketsandMarkets, defines and segments the Amaranth Seed ... the market size in terms of value. The ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
... Sept. 21, 2011 Reportlinker.com announces that a ... catalogue: Generic Drugs: The ... http://www.reportlinker.com/p0619264/Generic-Drugs-The-Global-Market-Focus-on-the-Americas.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment ... examination of the strategies employed by companies specializing ...
... SAN DIEGO, Sept. 20, 2011 Orexigen® Therapeutics, Inc. ... a recent meeting with senior officials in FDA,s Office ... detailing OND,s design requirements for a cardiovascular outcomes trial ... Letter (CRL) received in January 2011. Orexigen believes that ...
Cached Medicine Technology:Generic Drugs: The Global Market: Focus on the Americas 2Generic Drugs: The Global Market: Focus on the Americas 3Generic Drugs: The Global Market: Focus on the Americas 4Generic Drugs: The Global Market: Focus on the Americas 5Generic Drugs: The Global Market: Focus on the Americas 6Generic Drugs: The Global Market: Focus on the Americas 7Generic Drugs: The Global Market: Focus on the Americas 8Generic Drugs: The Global Market: Focus on the Americas 9Generic Drugs: The Global Market: Focus on the Americas 10Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 2Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 3Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 4Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 5
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by ... Monitoring For Drug Abuse Trends , Outbreaks (8/20), the National ... attempt to monitor drug abuse trends by turning to social ... drug abuse trends, it is also working with the University ... National Drug Early Warning System, which will be funded by ...
(Date:8/29/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Glass microfiber including its ... explores global and China’s top manufacturers of Glass ... and market share etc. , The report further ...
(Date:8/29/2014)... August 29, 2014 Dr. Parsa Mohebi M.D. ... of hair loss achieve great results in hair transplantation. ... Hair Transplant , an FUE method that harvests facial hair ... This method lets patients whose hair loss classification is 5 ... Transplant is a great alternative for those advanced hair loss ...
(Date:8/29/2014)... -- Astronauts may be at heightened risk of ... systems, a new study suggests. That could be ... the moon and Mars undertaken in the future, because ... be dangerous, NASA researchers say. They found that ... International Space Station crew members remains relatively unchanged during ...
(Date:8/29/2014)... 2014 Healthpointe Medical Group, one ... medical center from LAXMed. The medical center is less than ... miles west of the 405 freeway. , The LAX ... new LAX center is located at: 8610 S. Sepulveda Blvd., ... Healthpointe LAX office will provide the same comprehensive ...
Breaking Medicine News(10 mins):Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2
... Mayo Clinic review of patients responses to a drug ... general surgery questions a U.S. Food and Drug Administration ... appears in the current issue of the journal Anesthesiology. ... 2001 over concerns that the drug contributed to potentially ...
... This Decade ... OAKLAND, Calif., Sept. 28 Registered nurses at up to 16,Northern ... a major strike in October that could involve up to 5,500 ... Group in Yuba City and Marysville. Strike notices are being ...
... Center at Jefferson in Philadelphia have discovered new molecular ... breast cancer. They have found that prolactin, a pituitary ... initiates a new signaling pathway that may regulate the ... The work, which appears this month in the journal ...
... of William V. Corr, Executive Director, Campaign for,Tobacco-Free ... is a,statement of William V. Corr, Executive Director, ... will fall further behind in protecting,workers and the ... as two,more states - neighboring Maryland and Minnesota ...
... Insurance,Holdings, Inc. ("EIHI") (Nasdaq: EIHI ) announced ... Insurance Group ("EAIG") in the new position of,Regional ... an,indirect wholly-owned subsidiary of EIHI. EAIG entered ... licenses to underwrite in North Carolina, Virginia,Georgia and ...
... Cross,announces it has signed new three-year contracts with ... part of Catholic Health East health care,system, effective ... includes Mercy Fitzgerald Hospital, Mercy,Hospital of Philadelphia, Mercy ... Hospital, as well as Mercy Home Health and ...
Cached Medicine News:Health News:Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary 2Health News:RNs to Announce October Strike of 5,500 Nurses 2Health News:Jefferson researchers uncover new evidence of prolactin's possible role in breast cancer 2Health News:Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit 2Health News:Eastern Alliance Insurance Group Appoints Cox Regional Marketing Director for Southeast 2Health News:Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center 2Health News:Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center 3
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: